CHMP recommends approval of Entyvio for ulcerative colitis or Crohn’s disease.- Takeda Pharma
Related news and insights
Bristol Myers Squibb announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
AbbVie has announced that Health Canada has approved Humira (adalimumab) for inducing and maintaining clinical remission in pediatric patients five years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids and/or azathioprine or 6- mercaptopurine or who are intolerant to such therapies.
Eli Lilly and Company has announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase III induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC).